Literature DB >> 18286686

Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma.

Paras Jethwa1, Mushal Naqvi, Robert G Hardy, Neil-A Hotchin, Sally Roberts, Robert Spychal, Chris Tselepis.   

Abstract

AIM: To characterise expression of known E-cadherin repressors; Snail, Slug and Twist in the development of esophageal adenocarcinoma.
METHODS: E-cadherin, Slug, Snail and Twist mRNA expression in Barrett's metaplasia and esophageal adenocarcinoma specimens was examined by real-time reverse transcription-polymerase chain reaction (RT-PCR). Semi-quantitative immunohistochemistry was used to examine cellular localisation and protein levels. The effect of Slug on epithelial mesenchymal transition (EMT) markers was examined by transfection of Slug into an adenocarcinoma line OE33.
RESULTS: Cellular localisation of Slug in Barrett's metaplasia was largely cytoplasmic whilst in adenocarcinoma it was nuclear. Semi-quantitative analysis indicated that Slug was more abundant in adenocarcinoma compared to matched Barrett's metaplastic specimens. Snail and Twist were expressed in adenocarcinoma but were cytoplasmic in location and not induced compared to Barrett's mucosa. These observations were supported by mRNA studies where only Slug mRNA was shown to be over-expressed in adenocarcinoma and inversely correlated to E-cadherin expression. Overexpression of Slug in OE33 mediated E-cadherin repression and induced the mesenchymal markers vimentin and fibronectin.
CONCLUSION: Progression to adenocarcinoma is associated with increased Slug expression and this may represent a mechanism of E-cadherin silencing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18286686      PMCID: PMC2689407          DOI: 10.3748/wjg.14.1044

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells.

Authors:  E Batlle; E Sancho; C Francí; D Domínguez; M Monfar; J Baulida; A García De Herreros
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

Review 2.  Cadherins and catenins: role in signal transduction and tumor progression.

Authors:  J Behrens
Journal:  Cancer Metastasis Rev       Date:  1999       Impact factor: 9.264

3.  E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: an immunohistochemical and immunoblot study.

Authors:  S Swami; S Kumble; G Triadafilopoulos
Journal:  Am J Gastroenterol       Date:  1995-10       Impact factor: 10.864

4.  Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma.

Authors:  S J Hughes; Y Nambu; O S Soldes; D Hamstra; A Rehemtulla; M D Iannettoni; M B Orringer; D G Beer
Journal:  Cancer Res       Date:  1997-12-15       Impact factor: 12.701

5.  Barrett's metaplasia.

Authors:  J A Jankowski; R F Harrison; I Perry; F Balkwill; C Tselepis
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

6.  Acidic fibroblast growth factor is expressed sequentially in the progression from Barrett's esophagus to esophageal adenocarcinoma.

Authors:  R A Soslow; C G Petersen; H Remotti; N Altorki
Journal:  Dis Esophagus       Date:  2001       Impact factor: 3.429

7.  Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.

Authors:  C A Eads; R V Lord; S K Kurumboor; K Wickramasinghe; M L Skinner; T I Long; J H Peters; T R DeMeester; K D Danenberg; P V Danenberg; P W Laird; K A Skinner
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

8.  Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation.

Authors:  T Bailey; L Biddlestone; N Shepherd; H Barr; P Warner; J Jankowski
Journal:  Am J Pathol       Date:  1998-01       Impact factor: 4.307

9.  Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7.

Authors:  Jurjen J Boonstra; Albertina W van der Velden; Erwin C W Beerens; Ronald van Marion; Yuiko Morita-Fujimura; Yasuhisa Matsui; Tetsuro Nishihira; Chris Tselepis; Pierre Hainaut; Anson W Lowe; Berna H Beverloo; Herman van Dekken; Hugo W Tilanus; Winand N M Dinjens
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

10.  E-cadherin gene mutations are rare in adenocarcinomas of the oesophagus.

Authors:  B P Wijnhoven; N J de Both; H van Dekken; H W Tilanus; W N Dinjens
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

View more
  36 in total

Review 1.  Risk factors for neoplastic progression in Barrett's esophagus.

Authors:  Elizabeth F Wiseman; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

2.  Clinicopathologic significance of slug expression in human intrahepatic cholangiocarcinoma.

Authors:  Ke-Jun Zhang; Bing-Yuan Zhang; Kun-Peng Zhang; Li-Min Tang; Shi-Song Liu; Dong-Ming Zhu; Dian-Liang Zhang
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

Review 3.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

4.  Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.

Authors:  Olga Chemnitzer; Katharina Götzel; Luisa Maurer; Arne Dietrich; Uwe Eichfeld; Orestis Lyros; Boris Jansen-Winkeln; Albrecht Hoffmeister; Ines Gockel; René Thieme
Journal:  Dig Dis Sci       Date:  2017-10-30       Impact factor: 3.199

5.  miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.

Authors:  Cameron M Smith; David I Watson; Mary P Leong; George C Mayne; Michael Z Michael; Bas P L Wijnhoven; Damian J Hussey
Journal:  World J Gastroenterol       Date:  2011-02-28       Impact factor: 5.742

6.  Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133(+) pancreatic cancer cells.

Authors:  Koichiro Tsukasa; Qiang Ding; Makoto Yoshimitsu; Yumi Miyazaki; Shyuichiro Matsubara; Sonshin Takao
Journal:  Hum Cell       Date:  2015-05-22       Impact factor: 4.174

7.  In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation.

Authors:  Macarena Perán; Juan Antonio Marchal; Maria A García; Julian Kenyon; David Tosh
Journal:  Cell Oncol (Dordr)       Date:  2013-05-16       Impact factor: 6.730

8.  Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study.

Authors:  A Stoyianni; G Pentheroudakis; H Benjamin; A Cervantes; K Ashkenazi; G Lazaridis; N Pavlidis; Y Spector
Journal:  Clin Transl Oncol       Date:  2013-11-27       Impact factor: 3.405

9.  Expression of transcription factors snail, slug, and twist in human bladder carcinoma.

Authors:  Qinchao Yu; Kejun Zhang; Xinsheng Wang; Xiangping Liu; Zemi Zhang
Journal:  J Exp Clin Cancer Res       Date:  2010-09-01

10.  Helicobacter pylori potentiates epithelial:mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7.

Authors:  Yinfei Yin; Anna M Grabowska; Philip A Clarke; Elisabeth Whelband; Karen Robinson; Richard H Argent; Amanda Tobias; Rajendra Kumari; John C Atherton; Susan A Watson
Journal:  Gut       Date:  2010-06-28       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.